PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
3137079-6	1988	Adrenal demedullation partly inhibited but did not completely abolish the effect of TRH on IBAT blood flow and lessened the increase in serum adrenaline caused by TRH.	Epinephrine	142-152	thyrotropin releasing hormone	Rattus norvegicus	163-166	
2512185-2	1989	The intravenous administration of 50 micrograms of TRH produced an increase in plasma epinephrine, cerebral dopamine and a reciprocal decrease in norepinephrine and dopamine in diencephalon and midbrain.	Epinephrine	86-97	thyrotropin releasing hormone	Rattus norvegicus	51-54	
2551657-1	1989	TSH-releasing factor (TRF), administered into the lateral cerebroventricle of adult male rats, elevated plasma concentrations of ACTH, epinephrine, and norepinephrine.	Epinephrine	135-146	thyrotropin releasing hormone	Rattus norvegicus	0-20	
2551657-1	1989	TSH-releasing factor (TRF), administered into the lateral cerebroventricle of adult male rats, elevated plasma concentrations of ACTH, epinephrine, and norepinephrine.	Epinephrine	135-146	thyrotropin releasing hormone	Rattus norvegicus	22-25	
1835988-1	1991	Intrathecal administration of thyrotropin-releasing hormone (TRH) resulted in an increase in plasma epinephrine (E) and glucose levels in conscious rats.	Epinephrine	100-111	thyrotropin releasing hormone	Rattus norvegicus	30-59	
2891452-5	1988	The plasma levels of norepinephrine and epinephrine were increased by TRH, while there was no change in plasma renin activity or vasopressin.	Epinephrine	24-35	thyrotropin releasing hormone	Rattus norvegicus	70-73	
3080257-3	1986	In contrast, following TRH administration (4 mg/kg, iv), an increase in mean arterial pressure was associated with significant increases in plasma epinephrine, norepinephrine, and corticosterone.	Epinephrine	147-158	thyrotropin releasing hormone	Rattus norvegicus	23-26	
6813757-7	1982	It was found that intracerebroventricular pretreatment of animals with TRH, although causing no change in the epinephrine-induced pressor effect, did reduce the epinephrine-induced reflex bradycardia in rats.	Epinephrine	161-172	thyrotropin releasing hormone	Rattus norvegicus	71-74	
9722189-9	1998	The plasma levels of epinephrine, norepinephrine, and glucagon rose significantly after TRH.	Epinephrine	21-32	thyrotropin releasing hormone	Rattus norvegicus	88-91	
8845008-8	1996	administration of thyrotropin releasing hormone (TRH) (10 nmol/animal) also induced increases in plasma levels of adrenaline and noradrenaline, however, these increases were not modified by i.c.v.	Epinephrine	114-124	thyrotropin releasing hormone	Rattus norvegicus	18-47	
7862266-3	1994	All TRH doses studied enhanced blood pressure and noradrenaline and adrenaline secretion.	Epinephrine	53-63	thyrotropin releasing hormone	Rattus norvegicus	4-7	
1835988-1	1991	Intrathecal administration of thyrotropin-releasing hormone (TRH) resulted in an increase in plasma epinephrine (E) and glucose levels in conscious rats.	Epinephrine	100-111	thyrotropin releasing hormone	Rattus norvegicus	61-64	
1681438-6	1991	These observations suggest that TRH-induced hyperglycemia results from at least two effects: a direct neural effect on the liver including a suppressive effect of epinephrine on insulin secretion (contributing about 79% to the total hyperglycemic effect) and a direct effect of epinephrine on the liver (contributing about 21% to the total hyperglycemic effect).	Epinephrine	163-174	thyrotropin releasing hormone	Rattus norvegicus	32-35	
1681438-6	1991	These observations suggest that TRH-induced hyperglycemia results from at least two effects: a direct neural effect on the liver including a suppressive effect of epinephrine on insulin secretion (contributing about 79% to the total hyperglycemic effect) and a direct effect of epinephrine on the liver (contributing about 21% to the total hyperglycemic effect).	Epinephrine	278-289	thyrotropin releasing hormone	Rattus norvegicus	32-35	
2113409-4	1990	administration of TRH (0.6 and 3 nmol) at the T8-10 vertebral level resulted in a dose-related increase in epinephrine (E), norepinephrine (NE), and glucose levels, which was suppressed by prior administration of the ganglionic blocker, hexamethonium (1.5 mg/100 g b.	Epinephrine	107-118	thyrotropin releasing hormone	Rattus norvegicus	18-21